ll 37
Regeneration vs degeneration — where this fits
The body is always doing two things at once: breaking down (degeneration) and building back (regeneration). A condition persists when breakdown outruns repair. Most drugs used for symptoms suppress a signal (pain, acid, anxiety, inflammation) without fixing the tissue that caused the signal. Peptides in this ledger are studied for repair pathways: new blood vessels, repair-cell migration, nerve regrowth, gut lining, neural connections. This article maps one compound through that frame — what it is, how it is proposed to work, what evidence exists, and what people report.
Why it would work (logic chain)
No mechanism chain catalogued yet.
How many people take it
There is no reliable global count of how many people take this compound. That number is not in this ledger.
What we can count from this ledger:
- 0 anecdote source(s) (posts, threads, comments)
- 0 anecdote-tier claim(s) derived from them
Logic: Without catalogued Reddit/X posts, this article cannot answer how many people take it — only what studies exist.
Evidence inventory
This is a count of what is in this ledger — not a claim about all research worldwide.
- Scientific sources catalogued (PubMed, trials, reviews): 20
- Claims tagged human evidence: 0
- Claims tagged preclinical (animal/lab): 0
- Claims tagged anecdotal: 0
- Reddit posts catalogued: 0
- X posts catalogued: 0
- Other anecdote sources (YouTube, Instagram, etc.): 0
- Total sources in chain: 20
Logic: Studies exist in the ledger, but none are graded as strong human proof for the uses people discuss online. Animal and lab work is not the same as proof in people.
Logic: No social posts catalogued yet — we cannot report what people are saying on Reddit or X from this ledger.
Quantified confidence (this ledger): 0.25 / 1.00 — low — animal and anecdote heavy
Formula: human claims×0.12 + preclinical×0.04 + anecdote×0.015 + studies (capped). This is not clinical certainty — it measures how much graded evidence is catalogued here.
What scientists say
Decoding LL-37: Structure and antimicrobial mechanisms ... (source s1)
Details structure, broad antimicrobial activity of LL-37 against bacteria, fungi, viruses.
Evidence type: Published research.
LL-37 antimicrobial peptide: Molecular characterisation ... (source s2)
Narrative review on LL-37 in oral health and disease, 2026 publication.
Evidence type: Published research.
Antimicrobial Peptides of the Cathelicidin Family: Focus on ... (source s3)
Review focusing on LL-37 and modifications for therapies, 2025.
Evidence type: Published research.
Significance of the LL-37 Peptide Delivered from Human ... (source s4)
Explores LL-37 in sepsis treatment contexts, 2025.
Evidence type: Published research.
Human cathelicidin LL-37 rapidly disrupted colonic ... (source s5)
Study on LL-37 effects on colonic epithelium and tight junctions, 2025.
Evidence type: Published research.
Human antimicrobial/host defense peptide LL-37 may ... (source s6)
Update on LL-37 preventing infection spread, 2025 review.
Evidence type: Published research.
LL-37, the master antimicrobial peptide, its multifaceted ... (source s7)
Review on LL-37 roles in infections to cancer immunity, 2025.
Evidence type: Published research.
Antimicrobial peptide LL-37 increases rhinovirus-induced ... (source s8)
LL-37 effects on rhinovirus and immunomodulation, 2025.
Evidence type: Published research.
Study of cathelicidin (LL-37) immunoexpression in the skin ... (source s9)
Immunoexpression study of LL-37 in vitiligo, 2025.
Evidence type: Published research.
LL-37 and citrullinated-LL-37 modulate IL-17A/F-mediated ... (source s10)
Modulation of IL-17 by LL-37 variants, 2025 study.
Evidence type: Published research.
Cathelicidin LL-37 in periodontitis: current research progress and prospects (source s11)
Review on LL-37 expression and roles in periodontitis pathogenesis and treatment.
Evidence type: Published research.
Exploring the Role of Cathelicidin LL-37 and Ceragenins in Wound Healing (source s12)
Review on LL-37 and ceragenins in wound healing.
Evidence type: Published research.
Vitamin D-inducible antimicrobial peptide LL-37 binds SARS-CoV-2 Spike, ORF7a, and ORF8 proteins and inhibits viral replication (source s13)
LL-37 binds SARS-CoV-2 proteins and inhibits replication.
Evidence type: Published research.
LL-37 and bacterial DNA complexes in dental plaque (source s14)
Review on LL-37 and bacterial DNA in dental plaque.
Evidence type: Published research.
Vicenin-2 attenuates rosacea-like inflammation by targeting the IL-17RA/NF-κB pathway (source s15)
LL-37-induced rosacea model and anti-inflammatory effects.
Evidence type: Published research.
LL-37-derived peptide shows promising antimicrobial ... (source s16)
Study on LL-37-derived peptides for antimicrobial activity.
Evidence type: Published research.
CRISPR/Cas9-engineered Salmonella phage displaying ... (source s17)
Research on LL-37 engineered phages for antibacterial effects.
Evidence type: Published research.
Structural determinants of glycosaminoglycan ... (source s18)
LL-37's role in cancer and glycosaminoglycan interactions.
Evidence type: Published research.
---
Not medical advice. Counts and quotes are from this article's hash-chained ledger. Anecdote = real reports, not proof. Animal studies ≠ human proof.
Ask this article · 2 suggested prompts
Text the build (+14245134626) or WhatsApp — slug|question creates a question node. Paste evidence with ingest slug|q:NODE_ID|your paste.